Waltham, MA-based Altus Pharmaceuticals, a developer of protein-based drugs, revealed in an SEC filing yesterday that it decided last week “wind down” the company’s operations. The company is also ending a mid-stage clinical trial to test its growth hormone deficiency drug ALTU-238 in children.
